Introduction of point-of-care blood testing in early intervention in psychosis services: effects on physical health screening.
Lyman M. et al, (2025), Br J Psychiatry, 1 - 6
Protecting and promoting editorial independence - CORRIGENDUM.
Bhui K. et al, (2025), Br J Psychiatry
FREQ-NESS Reveals the Dynamic Reconfiguration of Frequency-Resolved Brain Networks During Auditory Stimulation.
Rosso M. et al, (2025), Adv Sci (Weinh)
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders.
De Giorgi R. et al, (2025), J Neurol Neurosurg Psychiatry
The therapeutic potential of exercise in post-traumatic stress disorder and its underlying mechanisms: A living systematic review of human and non-human studies
Wright S. et al, (2025), Wellcome Open Research, 9, 720 - 720
Ethnicity and involuntary hospitalisation: a study of intersectional effects
Ali R. et al, (2025), Social Psychiatry and Psychiatric Epidemiology
Missing a trick? Bupropion for the pharmacological treatment of depression in the UK.
Browning M. and Cowen PJ., (2025), Br J Psychiatry, 1 - 3
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.
Addington J. et al, (2025), Schizophrenia (Heidelb), 11
Technology Matters: Online Support and Intervention (OSI) for child anxiety problems - an example of the journey from research to practice.
Chessell C. et al, (2025), Child Adolesc Ment Health
Effect of lithium on circadian activity level and flexibility in patients with bipolar disorder: results from the Oxford Lithium Trial.
Xu N. et al, (2025), EBioMedicine, 115
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.
Harms MP. et al, (2025), Schizophrenia (Heidelb), 11
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK.
Cleare AJ. et al, (2025), Lancet Psychiatry, 12, 276 - 288
Clinical care for patients at risk of psychosis related violence.
Fazel S. and Lennox B., (2025), BMJ, 389
Clozapine and treatment-resistant schizophrenia: efficacy versus effectiveness.
Siskind D. et al, (2025), Lancet Psychiatry, 12, 240 - 241
Evaluating Traditional, Deep Learning and Subfield Methods for Automatically Segmenting the Hippocampus From MRI.
Sghirripa S. et al, (2025), Hum Brain Mapp, 46
The role of esketamine in persistent long COVID with predominant psychiatric manifestations.
Bozic I. et al, (2025), Eur Neuropsychopharmacol, 93, 66 - 67